Background: The optimal regimen of chemotherapy and reirradiation (re-XRT) for recurrent head and neck squamous cell carcinoma (HNSCC) is controversial. We report the final outcomes of a multicenter phase II trial evaluating cetuximab and cisplatin-based chemotherapy concurrent with re-XRT for patients with recurrent HNSCC.
Introduction
External-beam radiation therapy (XRT) remains essential in treatment of head and neck squamous cell carcinoma (HNSCC). After XRT, locoregional failure remains a significant cause of cancer-related mortality [1] . Besides locoregional failure, HNSCC patients have a high incidence of secondary cancers within the XRT field [2, 3] . If a patient has persistent, recurrent or metachronous HNSCC after XRT, salvage surgery is generally recommended [4] . Many recurrences, however, are not resectable or inoperable due to patients' comorbidities [5] . Furthermore, patients who undergo resection often have high-risk factors for local recurrence such as positive/close margins or extracapsular nodal extension. As such reirradiation (re-XRT) has been used in patients with recurrent HNSCC and reported in both retrospective studies [6, 7] and prospective clinical trials [8] [9] [10] .
In the primary treatment of locally advanced HNSCC, combining XRT with systemic agents has been shown to improve survival outcomes [11] . In particular, cisplatin-based chemotherapy has a prominent radiosensitization effect that has translated into a survival benefit [11] . Furthermore, adjuvant re-XRT with chemotherapy after surgical resection has shown a disease-free survival benefit over surgical resection alone [10] .
Targeted biologic agents have also been utilized concurrently with XRT in the primary treatment of HNSCC with improved survival outcomes. Cetuximab, an epidermal growth factor receptor (EGFR) antibody which capitalizes on the fact that most HNSCCs overexpress EGFR [12, 13] , has shown radiosensitization effects both in vitro [14] and in vivo [15] . A phase III trial has shown that concurrent cetuximab with XRT has an overall survival (OS) benefit over XRT alone in the definitive treatment of locally advanced HNSCC [16] .
In patients receiving re-XRT for recurrent HNSCC, both cisplatin [9] and single-agent cetuximab [17] [18] [19] [20] [21] [22] [23] have been used concurrently with re-XRT with modest outcomes. Further, in the phase III trial RTOG 0522, the combination of cisplatin and cetuximab has been utilized concurrently with XRT in the treatment of primary HNSCC without improved efficacy over cisplatin alone [24] . However, to our knowledge, the combination of concurrent cisplatin and cetuximab has not been tested with re-XRT. As such, we developed a multi-institutional phase II trial combining cisplatin and cetuximab with re-XRT for patients with recurrent or secondary HNSCC. We report toxicity and survival outcomes from this trial.
Materials and methods
Methods are summarized below with additional information detailed in the supplementary data, available at Annals of Oncology online.
Patient eligibility and baseline assessment
Institutional review board approval was obtained for each trial institution. Eligible patients were 18 years or older, had pathologically confirmed recurrence of squamous cell carcinoma or a second HNSCC (excluding nasopharynx and salivary gland), with no distant metastases, with more than 6 months from prior radiation treatment, and had not received any systemic chemotherapy for the recurrent disease. It was also required that at least 75% of the recurrent tumor be in an area previously irradiated to at least 45 Gy but not exceeding a maximum dose of 75 Gy.
Patients who received radiation with either concurrent cisplatin alone or concurrent cetuximab alone in the first course of treatment were eligible due to a hypothesized synergistic effect of the combination overcoming chemoresistance, but patients who previously received radiation with both concurrent cisplatin and cetuximab were not eligible. Patients who had unresectable disease or underwent surgical resection of their recurrence with positive margins were eligible. All patients were required to have a Karnofsky Performance Status of at least 70, and adequate bone marrow, renal and hepatic functions to tolerate chemotherapy.
Protocol treatment
The complete protocol schema is summarized in supplementary Figure S1 , available at Annals of Oncology online.
Chemotherapy
Treatment was administered on an outpatient basis. A loading dose of Cetuximab 400 mg/m 2 was administered intravenously over 120 min 5-9 days before radiation and chemotherapy. Then, cetuximab 250 mg/m 2 and cisplatin 30 mg/m 2 were administered intravenously weekly concurrently with XRT.
Radiotherapy
Re-XRT was delivered using standard once daily fractionation, 5 days a week (excluding holidays). All patients were treated using intensitymodulated radiotherapy (IMRT) with image guidance with immobilization in a thermoplastic mask. For treatment planning, gross tumor volume (GTV) was defined as all visible disease in treatment planning computed tomography (CT) or positron emission tomography (PET)-CT images or tumor bed for patients who had surgical resection. Clinical target volume (CTV) was created by adding 0.5-1.0 cm to GTV. The planning target volume (PTV) margin of 5 mm was typically used but could be reduced to as little as 1 mm in regions adjacent to the spinal cord or brainstem. Elective (uninvolved) lymphatic regions were not included in the radiation field. The dose prescribed to the PTV was 60 Gy in 30 fractions, with an elective simultaneous integrated boost to the GTV to a total dose of 66 Gy in 30 fractions at the discretion of the prescribing radiation oncologist. The maximal cumulative point dose to the spinal cord could not exceed 54 Gy and to the brainstem could not exceed 60 Gy.
Study evaluation and assessment of response
Adverse effects were evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Patients were evaluated at least weekly during concurrent chemoradiation in radiation oncology and/or medical oncology clinics. Patients were seen in follow-up 1 month after treatment completion, then every 3 months in the first 2 years and every 6 months up to 5 years from treatment completion. CT scan of the head and neck and/or PET-CT was obtained 3 months after completion of XRT and if clinically indicated.
Study objectives and statistical considerations
The primary end point of the study was 1-year OS. Secondary end points included recurrence-free survival (RFS) and both acute and late toxicities.
Sample size was calculated based on the assumption that half of the patients undergoing re-XRT underwent surgical resection with microscopic disease and the other half did not undergo surgical resection. Historical outcomes estimate the 1-year OS for patients with microscopic disease undergoing re-XRT at 60% [10] and for patients not undergoing resection before re-XRT at 50% [9] . Assuming the proposed treatment yields a hazard reduction for death of 0.5, we estimate a 1-year OS of 73% in our study population. Assuming a 5% ineligibility/inevaluability rate, the total sample size required was 48 patients.
Survival end points were measured from the day of study registration. For RFS, progression was defined as first evidence of locoregional progression or recurrence, distant metastasis or death from any cause. Survival probabilities were estimated using the Kaplan-Meier method. Univariate analyses of survival outcomes were performed with the logrank test for categorical variables and Cox Proportional hazards regression for continuous variables. A P ¼ 0.05 was considered statistically significant.
Results

Patient characteristics
From March 2009 until May 2013, 48 patients were enrolled. Three patients were not evaluable: two did not begin treatment on study and one did not complete the protocol treatment. Patient characteristics of patients that completed treatment are summarized in Table 1 . The median age was 62 years (range: 36-85 years). Thirty-three patients were male and 12 were female. Median time from completion of prior XRT to start of retreatment was 2.5 years (range: 0.5-18.3 years). Thirty-three (73.3%) patients were treated after surgical resection.
Treatment delivery and toxicities
Of 46 patients that began treatment on study, only 1 patient did not complete protocol treatment and only received 3 cycles of chemotherapy as the patient elected to withdraw from the study.
Acute toxicities are summarized in Table 2 . There were no grade 5 toxicities. There were 10 patients grade 4 toxicities: 4 patients with lymphopenia (8.7%), 1 patient with leukopenia (2.2%), 1 patient with neutropenia (2.2%), 1 patient with anemia (2.2%), 2 patients with infection (4.3%) and 1 patient with dermatitis (2.2%). The most common grade 3 or higher toxicity was lymphopenia in 21 patients (46%). Other common grade 3 toxicities included anorexia (5 patients, 10.9%), dysphagia (8 patients, 17.4%), mucositis (5 patients, 10.9%), dermatitis (5 patients, 10.9%), pain (10 patients, 21.7%) and a variety of electrolyte abnormalities including hyponatremia (3 patients, 6.5%) and hypophosphatemia (3 patients, 6.5%).
No grade 4 or 5 late toxicities were observed. Grade 3 late toxicities were observed in eight patients (17.4%) as follows: lymphopenia in two patients (4.3%), esophageal stenosis in one patient, dysphagia in three patients (6.5%), radiation dermatitis in one patient (2.2%) and a pneumonia deemed treatment related in one patient (2.2%). There were no reported nonhealing wounds, fistulas, osteoradionecrosis or carotid blowouts.
Treatment efficacy and prognostic factors
Median follow-up for all 45 patients who were on study was 1.38 years and for the 25 patients still alive was 3.94 years. The 1-year and 2-year OS were 60.4% and 45.3%, respectively. Twenty-seven of 45 patients had disease relapse at last follow-up. The 1-year and 2-year RFS were 34.1% and 27.3%, respectively. Kaplan-Meier curves for OS and RFS are shown in Figure 1 . The majority of recurrences occurred within the first year. Patients who underwent surgery before re-XRT had higher absolute 1-year OS (71.3% versus 33.3%) and 2-year OS (50.4% versus 33.3%) compared with those that received re-XRT alone, but this did not reach statistical significance (supplementary Figure S2 , available at Annals of Oncology online, P ¼ 0.226).
Prognostic factors for OS were evaluated on univariate analysis. Only younger age was associated with improved OS (P ¼ 0.01, age as a continuous variable). Salvage surgery, time from previous RT course (as a continuous variable) and higher RT dose level (66 Gy) were not associated with improved OS.
Discussion
We report here a phase II clinical trial using the combination of concurrent cisplatin and cetuximab with re-XRT in the management of recurrent or second primary HNSCC. The regimen was feasible with limited late toxicities.
At least six retrospective studies utilizing single-agent cetuximab with re-XRT in recurrent HNSCC have been reported. These are summarized in the supplementary table S1, available at Annals of Oncology online [17] [18] [19] [20] [21] 23] . Four of these studies used 1.8 Gy fractions to the GTV plus a margin [17, 18, 20, 23] , confirming the tolerability of utilizing concurrent cetuximab with conventionally fractionated re-XRT in the recurrent HNSCC setting. All of these studies reported similar 1-year OS ranging from 34.8% to 44%. This compares poorly with our observed 1-year OS of 60.4% with the combination of cetuximab and cisplatin with re-XRT. However, all patients included in these studies had inoperable/unresectable recurrent HNSCC except four patients in one study [23] , while 73.3% of patients in our study had salvage surgery before re-XRT. Two studies utilized stereotactic body radiotherapy (SBRT) with concurrent single-agent cetuximab [19, 21] . Concurrent cetuximab with SBRT was well tolerated and the reported 1-year OS from both studies (40% and 47.5%) was comparable with conventional fractionation re-XRT with cetuximab, suggesting SBRT is a well-tolerated alternative in re-XRT in selected patients. However, studies using SBRT may have significant selection bias as SBRT can only be performed for patients with smaller disease burden amenable to the technique. A conventional re-XRT regimen such as the one in this trial should be considered in patients not candidates for SBRT.
Our study is the first to evaluate the safety and efficacy of a combination of concurrent cetuximab and cisplatin with re-XRT in recurrent HNSCC. Although RTOG 0522 did not demonstrate a survival benefit with the combination of concurrent cetuximab and cisplatin over concurrent cisplatin alone in the primary treatment of HNSCCs [24] , our trial was designed before these results were reported. However, the scientific rationale for further examination of concurrent cetuximab plus cisplatin in the re-XRT setting is sound given the biologic differences of primary locally advanced HNSCC versus recurrent or second primary HNSCC occurring in a previously irradiated field. The majority of the patients treated with re-XRT have received prior chemotherapy with XRT, a poor prognostic factor for re-XRT with chemotherapy [25] . This observation suggests that drug resistance may be a prominent barrier in this population. Thus, the combination of re-XRT, chemotherapy, plus a biologic agent, such as cetuximab, may overcome drug-resistant clonogens, increasing efficacy compared with re-XRT with chemotherapy alone and is worthy of further evaluation.
We found that the treatment regimen was feasible. Only one patient receiving treatment did not complete the entire course of systemic therapy. This patient elected to withdraw from the study. The most common side effects were lymphopenia, mucositis, dysphagia and dermatitis; all expected from chemoradiation. The feasibility of our regimen likely relates to two important factors: limited re-XRT field using IMRT and cisplatin dose. By limiting the re-XRT field to the GTV plus a margin using IMRT, we were able to limit the extent of normal tissues treated with high cumulative radiation dose, thus limiting side effects and allowing the regimen to be more tolerable. Including elective nodal irradiation would have increased the toxicity of re-XRT, likely resulting in worse tolerability. Also, our weekly cisplatin dose of 30 mg/m amounts to a cumulative cisplatin dose of 180 mg/m 2 over 6 weeks, lower than the commonly used cumulative dose of 200 mg/m 2 thought to be required for cisplatin efficacy in the primary chemoradiation treatment setting [26] . This low cisplatin dose may further explain the excellent compliance with the regimen.
Our reported 1-year OS of 60.4% is similar when compared with other large prospective trials of re-XRT. In the large French trial of patients undergoing re-XRT after surgical resection, 1-year OS was approximately 60% [10] . In the two prospective RTOG re-XRT trials 9610 [8] and 9911 [9] , 1-year OS were 40.5% and 50.2%, respectively. All of the patients enrolled in the RTOG re-XRT trials did not have surgery for recurrent tumors, reflecting more advanced disease in the RTOG trials when compared with ours as only about onefourth of patients on our trial did not undergo surgical resection before re-XRT.
Examining only patients that had surgical resection before re-XRT in our trial, the 1-year OS of 71.3% is better than that reported in the French trial. Furthermore in the French trial, only 29% of patients had positive margins and 22.5% of patients had extracapsular extension. Patients in our trial represented much higher risk patients than the French study. The good survival outcome of our trial may reflect that our treatment regimen is more active than the 5-fluorouracil (5-FU) and hydroxyurea re-XRT regimen. However, these differences in outcomes may also be due to improved staging with the use of 2-fluoro-2-deoxy-D-glucose-PET or other factors reflecting the different eras in which these trials were conducted.
Furthermore, the regimen used in this trial is better tolerated than those used in other trials as there were no grade 5 toxicities. Both RTOG trials used highly aggressive re-XRT regimens with BID re-XRT and intensive chemotherapy regimens (daily 5-FU and hydroxyurea in 9610 and daily cisplatin and paclitaxel in 9911), resulting in approximately 8% grade 5 toxicity in both trials [8, 9] . In the French trial, four deaths (two acute and two late) were deemed treatment related [10] .
Caveats of this study include that it is a single-arm phase II trial across three institutions, that enrollment may have been limited by selection, and that it was conducted in an era in which the understanding of the impact of the human papilloma virus in HNSCC was in its infancy. In addition, the study population represents a mixture of patients who underwent surgery before re-XRT and patients who were considered unresectable before re-XRT. Nonetheless, the observed 60.4% 1-year OS may be reflective of the addition of cisplatin and cetuximab to high-dose re-XRT with IMRT to a limited field.
Conclusions
We report the final results of our phase II trial examining the combination of cisplatin, cetuximab and involved field re-XRT in the setting of recurrent HNSCC. The treatment regimen is feasible and provided good survival outcomes for patients undergoing re-XRT. Younger age was associated with a significant improvement in OS.
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